Does Dr. HISHAM ABUSAMHADANA have financial conflicts of interest?

Dr. HISHAM ABUSAMHADANA (MD) has received a total of $2,373 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $2,373 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. HISHAM ABUSAMHADANA?

According to CMS Open Payments data, Dr. HISHAM ABUSAMHADANA received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($523), JANSSEN PHARMACEUTICALS ($441), and E.R. SQUIBB & SONS, L.L.C ($275).

Does Dr. HISHAM ABUSAMHADANA receive research grants or speaking fees?

Dr. HISHAM ABUSAMHADANA has received $2,373 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. HISHAM ABUSAMHADANA

MDReal-Time Hydrated

Specialty: Family Medicine

Practice Location: ERIE, PA 16502

NPI Number: 1689087306

LIFETIME INDUSTRY VALUE

$2,373

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABUSAMHADANA is a verified Family Medicine practitioner based in ERIE, PA.

Between 2021 and 2024, Dr. ABUSAMHADANA had an overall industry promotional and research financial footprint of $2,373 as recorded in the federal CMS Open Payments database.

$2,373 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABUSAMHADANA's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $523 (representing 22% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$523

22%

JANSSEN PHARMACEUTICALS

Rank 2

$441

18.6%

E.R. SQUIBB & SONS, L.L.C

Rank 3

$275

11.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.